Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop
VG De Gruttola, P Clax, DL DeMets, GJ Downing… - Controlled clinical …, 2001 - Elsevier
We report on recommendations from a National Institutes of Health Workshop on methods
for evaluating the use of surrogate endpoints in clinical trials, which was attended by experts
in biostatistics and clinical trials from a broad array of disease areas. Recent advances in
biosciences and technology have increased the ability to understand, measure, and model
biological mechanisms; appropriate application of these advances in clinical research
settings requires collaboration of quantitative and laboratory scientists. Biomarkers, new …
for evaluating the use of surrogate endpoints in clinical trials, which was attended by experts
in biostatistics and clinical trials from a broad array of disease areas. Recent advances in
biosciences and technology have increased the ability to understand, measure, and model
biological mechanisms; appropriate application of these advances in clinical research
settings requires collaboration of quantitative and laboratory scientists. Biomarkers, new …